Document Type
Honors Thesis
Abstract
Alzheimer’s disease (AD) is a neurological condition that accounts for 60 to 70% of dementia. The neurotransmitter acetylcholine is thought to play a fundamental role in the propagation of memory and is a neurotransmitter of great importance in AD. Another neurotransmitter involved in the treatment of AD is glutamate via the NMDA receptor. While cholinergic medications and NDMA antagonists are available for the treatment of AD there remains a need to develop different medications that are more effectual for certain individuals My objective is to design pharmacologically active molecules to treat AD by utilizing knowledge of neuropharmacology, computational techniques, and the literature in order to generate molecules that have applications to better treat Alzheimer’s disease by modifying functional groups to increase receptor efficacy and affinity. Computational models demonstrated greater receptor affinity compared to currently available AD drugs. This shows that these compounds might be potentially useful in treating AD.
Publication Date
5-1-2016
Language
English
License
This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 International License.
Recommended Citation
Luciani, Kevin, "DRUG DISCOVERY: DEVELOPING NOVEL COMPOUNDS FOR THE TREATMENT OF ALZHEIMER’S DISEASE" (2016). 2016 Spring Honors Capstone Projects. 1.
https://mavmatrix.uta.edu/honors_spring2016/1